Disease knowledge level is a noteworthy risk factor of anxiety and depression in patients with chronic obstructive pulmonary disease: a cross-sectional study

BMC Pulmonary Medicine

Qianli Ma¹  Changzheng Wang¹  Min Wan¹  Xiuling Wu³  Xiuqing Liao²  Jiangrong Liao⁴  Qiao Zhang¹ 

[1] Institute of Respiratory Diseases, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China;Department of Respiratory Diseases, Fuling Central Hospital of Chongqing, Chongqing, China;Department of Respiratory Diseases, Armed Police General Hospital of Chongqing, Chongqing, China;Department of Respiratory Diseases, Guizhou Aerospace Hospital, Guizhou, China

关键词: Comorbidities;    Depression;    Anxiety;    Knowledge;    COPD;   

Others  :  862859
DOI  :  10.1186/1471-2466-14-92

 received in 2014-01-11, accepted in 2014-05-08,  发布年份 2014

【 摘 要 】

Background

Risk factors of anxiety and depression symptoms in patients with chronic obstructive pulmonary disease (COPD) have been widely researched, but most of them cannot be addressed clinically. The aim of this study was to investigate whether COPD knowledge level is a risk factor of anxiety and/or depression in COPD patients in addition to functional capacity and quality of life, and to determine the key topics of COPD knowledge.

Methods

A total of 364 COPD patients from four centers were recruited into this cross-sectional survey. Subjects’ general medical information, assessments of lung function, dyspnea, quality of life, and exercise capacity, and responses to the Hospital Anxiety and Depression Scale (HAD) and the Bristol COPD Knowledge Questionnaire (BCKQ) were collected. Partial correlation analysis was performed, and a multivariable model testing risk factors of anxiety and depression as well as a multivariable model of 13 topics of knowledge derived from BCKQ were constructed.

Results

Subjects with anxiety or depression were more likely to have less COPD knowledge. Partial correlation analysis revealed that HAD score was negatively correlated with BCKQ score (rho = −0.153, P = 0.004). BCKQ score was significant in the multivariable model that tested risk factors of anxiety and depression (P = 0.001, OR = 0.944). Topics of epidemiology (P < 0.001, OR = 0.653) and infections (P = 0.006, OR = 0.721) were significant in the multivariable model evaluating 13 topics.

Conclusions

The level of patients’ disease knowledge is a significant risk factor of anxiety and depression in COPD patients. Epidemiology and infections are key topics of COPD knowledge to target in the Chinese population.

Trial registration

ChiCTR-OCS-12002518

【 授权许可】

   
2014 Zhang et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Kunik ME, Roundy K, Veazey C, Souchek J, Richardson P, Wray NP, Stanley MA: Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest 2005, 127:1205-1211.
• [2]Lou P, Zhu Y, Chen P, Zhang P, Yu J, Zhang N, Chen N, Zhang L, Wu H, Zhao J: Prevalence and correlations with depression, anxiety, and other features in outpatients with chronic obstructive pulmonary disease in China: a cross-sectional case control study. BMC Pulm Med 2012, 12:53. BioMed Central Full Text
• [3]Zeng X, Chen F, Liu N, Xie S: Analysis of depression and anxiety in patients with chronic obstructive pulmonart disease. Mod Prev Med 2011, 38:3242-3243. 3245
• [4]Maurer J, Rebbapragada V, Borson S, Goldstein R, Kunik ME, Yohannes AM, Hanania NA, Anxiety AWPo, Depression in C: Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest 2008, 134:43S-56S.
• [5]Dahlen I, Janson C: Anxiety and depression are related to the outcome of emergency treatment in patients with obstructive pulmonary disease. Chest 2002, 122:1633-1637.
• [6]Hill K, Geist R, Goldstein RS, Lacasse Y: Anxiety and depression in end-stage COPD. Eur Respirat J 2008, 31:667-677.
• [7]Ng TP, Niti M, Tan WC, Cao Z, Ong KC, Eng P: Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 2007, 167:60-67.
• [8]Turan O, Yemez B, Itil O: The effects of anxiety and depression symptoms on treatment adherence in COPD patients. Prim Health Care Res Dev 2013, 1-8. http://www.ncbi.nlm.nih.gov/pubmed/23561004 webcite
• [9]Cleland JA, Lee AJ, Hall S: Associations of depression and anxiety with gender, age, health-related quality of life and symptoms in primary care COPD patients. Fam Pract 2007, 24:217-223.
• [10]Hanania NA, Mullerova H, Locantore NW, Vestbo J, Watkins ML, Wouters EF, Rennard SI, Sharafkhaneh A, Evaluation of CLtIPSEsi: Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med 2011, 183:604-611.
• [11]Cafarella PA, Effing TW, Usmani ZA, Frith PA: Treatments for anxiety and depression in patients with chronic obstructive pulmonary disease: a literature review. Respirology 2012, 17:627-638.
• [12]Coventry PA, Hind D: Comprehensive pulmonary rehabilitation for anxiety and depression in adults with chronic obstructive pulmonary disease: Systematic review and meta-analysis. J Psychosom Res 2007, 63:551-565.
• [13]Von Leupoldt A, Fritzsche A, Trueba AF, Meuret AE, Ritz T: Behavioral medicine approaches to chronic obstructive pulmonary disease. Ann Behav Med 2012, 44:52-65.
• [14]Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, Hill K, Holland AE, Lareau SC, Man WD, Pitta F, Sewell L, Raskin J, Bourbeau J, Crouch R, Franssen FM, Casaburi R, Vercoulen JH, Vogiatzis I, Gosselink R, Clini EM, Effing TW, Maltais F, van der Palen J, Troosters T, Janssen DJ, Collins E, Garcia-Aymerich J, Brooks D, Fahy BF: An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013, 188:e13-e64.
• [15]White R, Walker P, Roberts S, Kalisky S, White P: Bristol COPD Knowledge Questionnaire (BCKQ): testing what we teach patients about COPD. Chron Respir Dis 2006, 3:123-131.
• [16]From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Strategy for Diagnosis, Management, and Prevention of COPD [http://www.goldcopd.org/ webcite]
• [17]Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, Force AET: Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
• [18]Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA: Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999, 54:581-586.
• [19]Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-370.
• [20]Jones PW, Tabberer M, Chen WH: Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT) scores. BMC Pulm Med 2011, 11:42. BioMed Central Full Text
• [21]Laboratories ATSCoPSfCPF: ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111-117.
• [22]Bjelland I, Dahl AA, Haug TT, Neckelmann D: The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002, 52:69-77.
• [23]Zheng L, Wang Y, Li H: Application of Hospital Anxiety and Depression Scale in general hospital: an analysis in reliability and validity. Shanghai Arch Psychiatry 2003, 15:264-266.
• [24]Wan M, Zhang Q, Li Y, Wu Y, Wang C, Ma Q: Investigation of COPD awareness in patients with newly diagnosed COPD. Acta Academiae Medicinae Militaris Tertiae 2011, 33:2527-2529.
• [25]Van Manen JG, Bindels PJ, Dekker FW CJIJ, van der Zee JS, Schade E: Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax 2002, 57:412-416.
• [26]Emery CF, Schein RL, Hauck ER, MacIntyre NR: Psychological and cognitive outcomes of a randomized trial of exercise among patients with chronic obstructive pulmonary disease. Health Psychol 1998, 17:232-240.
• [27]Hynninen MJ, Bjerke N, Pallesen S, Bakke PS, Nordhus IH: A randomized controlled trial of cognitive behavioral therapy for anxiety and depression in COPD. Respir Med 2010, 104:986-994.
• [28]Zheng JP, Yang L, Wu YM, Chen P, Wen ZG, Huang WJ, Shi Y, Wang CZ, Huang SG, Sun TY, Wang GF, Xiong SD, Zhong NS: The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD. Chest 2007, 132:1756-1763.